Calcium phosphate drug delivery system: influence of local zoledronate release on bone implant osteointegration.
Despite total hip replacement (THR) gives generally satisfactory results, the quality of outcome in young patients is markedly decreased compared to the average THR outcome. For this population, pharmacological treatment with bisphosphonate would be beneficial to decrease the peri-implant osteolysis. However, as this population does not necessarily suffer from osteoporosis, a nonsystemic treatment would be preferable. Zoledronate was then grafted to hydroxyapatite (HA) coating of titanium implants. The implants were inserted in rat condyles with various zoledronate concentrations. A positive concentration-dependent effect was observed on the peri-implant bone density and on different histomorphometric parameters. Importantly for the outcome of the implants, the mechanical fixation was increased by the local presence of zoledronate. The obtained results open the way of an easy transformation of currently existing HA-coated implants by grafting bisphosphonate onto the coating in order to increase their service life in the patients.
Peter
B
B
Bone Bioengineering Group, Laboratory of Orthopedic Research, Swiss Federal Institute of Technology Lausanne, Switzerland.
Pioletti
D P
DP
Laïb
S
S
Bujoli
B
B
Pilet
P
P
Janvier
P
P
Guicheux
J
J
Zambelli
P-Y
PY
Bouler
J-M
JM
Gauthier
O
O
D000818:Animals; D002130:Calcium Phosphates / Q000008:administration & dosage*; D004164:Diphosphonates / Q000008:administration & dosage*; D016503:Drug Delivery Systems; D005260:Female; D007093:Imidazoles / Q000008:administration & dosage*; D008855:Microscopy, Electron, Scanning; D016348:Osseointegration; D019736:Prostheses and Implants; D051381:Rats; D017208:Rats, Wistar; D014025:Titanium; D000077211:Zoledronic Acid
D002130:Calcium Phosphates; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; C020243:calcium phosphate; D014025:Titanium